CTMX - CytomX Slumps On Data And Other News: The Good Bad And Ugly Of Biopharma
CytomX Stock Slumps on Disappointing Probody Data
CytomX Therapeutics (CTMX) slumped as the company provided updates about its two lead drug candidates CX-072 and CX-2009. The company had also recently reported its financial results for the first quarter of 2020 and offered business updates. CytomX has decided to terminate PROCLAIM-CX-072-002 study in melanoma.
For Cx-2009, the company reported data from Phase 1/2 study showed "evidence" of clinical activity at doses at least 4 mg/kg 3x/week. The study was designed to assess antibody-drug conjugate CX-2009 in patients with solid tumors. This bifurcated design study